Evidence map›Paper›PMID 25589617›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection.

Chun Chao, Michael J Silverberg, Lanfang Xu, Lie-Hong Chen, Brandon Castor, Otoniel Martínez-Maza, Donald I Abrams, Hongbin D Zha, Reina Haque, Jonathan Said

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Human Immunodeficiency Virus Related Non-Hodgkin's Lymphoma.Blood and lymphatic cancer : targets and therapy · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Chun ChaoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. chun.r.chao@kp.org.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Lanfang XuDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Lie-Hong ChenDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Brandon CastorDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California.
Otoniel Martínez-MazaDepartments of Obstetrics and Gynecology and Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, California. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California.
Donald I AbramsDepartment of Medicine and San Francisco General Hospital, University of California, San Francisco, San Francisco, California.
Hongbin D ZhaLos Angeles Medical Center, Kaiser Permanente Southern California, Los Angeles, California.
Reina HaqueDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Jonathan SaidDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California.
Kaiser Permanente · US

Funding

NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
National Neurological AIDS BankU01MH083500 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2008 to 2012
$7.2M
Prognostic Markers for HIV-Postive Diffuse Large B-Cell LymphomaR01CA134234 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHAO, CHUN R. · 2008 to 2011
$1.7M
NCI NIH HHS R01 CA134234NCI NIH HHS R01CA134234-01NIMH NIH HHS U01 MH083500NIMH NIH HHS U24 MH100929
6 · The paper itself

Abstract

purposeHIV-related diffuse large B-cell lymphoma (DLBCL) may be biologically different from DLBCL in the general population. We compared, by HIV status, the expression and prognostic significance of selected oncogenic markers in DLBCL diagnosed at Kaiser Permanente in California, between 1996 and 2007. EXPERIMENTAL

designEighty HIV-infected DLBCL patients were 1:1 matched to 80 HIV-uninfected DLBCL patients by age, gender, and race. Twenty-three markers in the following categories were examined using IHC: (i) cell-cycle regulators, (ii) B-cell activators, (iii) antiapoptotic proteins, and (iv) others, such as IgM. Tumor marker expression was compared across HIV infection status by Fisher exact test. For markers differentially expressed in HIV-related DLBCL, logistic regression was used to evaluate the association between tumor marker expression and 2-year overall mortality, adjusting for International Prognostic Index, cell-of-origin phenotype, and DLBCL morphologic variants.

resultsExpression of cMYC (% positive in HIV-related and -unrelated DLBCL: 64% vs. 32%), BCL6 (45% vs. 10%), PKC-β2 (61% vs. 4%), MUM1 (59% vs. 14%), and CD44 (87% vs. 56%) was significantly elevated in HIV-related DLBCLs, whereas expression of p27 (39% vs. 75%) was significantly reduced. Of these, cMYC expression was independently associated with increased 2-year mortality in HIV-infected patients [relative risk = 3.09 (0.90-10.55)] in multivariable logistic regression.

conclusionsThese results suggest that HIV-related DLBCL pathogenesis more frequently involves cMYC and BCL6 among other factors. In particular, cMYC-mediated pathogenesis may partly explain the more aggressive clinical course of DLBCL in HIV-infected patients.

Indexed as

ApoptosisApoptosis Regulatory ProteinsBiomarkers, TumorCell Cycle ProteinsDNA-Binding ProteinsFemaleHIV InfectionsHumansHyaluronan ReceptorsImmunoglobulin MInterferon Regulatory Factor-4Interferon Regulatory FactorsLymphocyte ActivationLymphoma, Large B-Cell, DiffuseMaleMiddle AgedApoptosis Regulatory ProteinsBCL6 protein, humanBiomarkers, TumorCD44 protein, humanCell Cycle ProteinsDNA-Binding ProteinsHyaluronan ReceptorsImmunoglobulin MInterferon Regulatory Factor-4Interferon Regulatory FactorsMYC protein, humanp27 antigenProliferating Cell Nuclear AntigenProtein Kinase C betaProto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-myc

Identifiers

PMID25589617
PMCPMC4378903
OpenAlexW1989901409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.